The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

Wed, 06th Nov 2019 11:00

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 100 - LOSERS

----------

BT Group, down 2.9%. Vodafone Group said its UK unit has agreed a five-year deal with Virgin Media to bring new services, including 5G, to more than three million mobile customers. Meanwhile, Vodafone noted Virgin Media's current agreement with BT Enterprise, which has been in place since January 2017, will come to an end in late 2021, at which point Virgin Media's mobile offering will transition to Vodafone. The new mobile virtual network operator agreement, which runs until 2026, will see Vodafone supply wholesale mobile network services, including both voice and data, to Virgin Mobile and Virgin Media Business. Telephone and internet services provider Virgin Media will also have full access to all of Vodafone's current services and future technologies. Vodafone was 1.0% higher.

----------

FTSE 250 - WINNERS

----------

Softcat, up 3.0%. Jefferies upgraded the IT infrastructure provider to Buy from Hold.

----------

Ultra Electronics, up 2.9%. The defence engineering company said there has been good order book development since interim results, and trading is in line with expectations. Ultra Electronics said for the nine months to September 30 there has been good order book development, as anticipated. The company said it continues to trade in line with expectations. The ongoing strategic evolution is progressing and there remains good long term opportunities and growth potential, Ultra Electronics asserted. "Our major markets are growing and our strong technology base is positioning us well on existing and potential future programs," it said.

----------

Marks & Spencer, up 2.4%. The retailer said its transformation plan is progressing rapidly as it makes up for "lost time" in its Clothing & Home unit, which saw a "difficult" first half. Revenue for the half-year to September 28 fell 2.1% to GBP4.86 billion, though pretax profit jumped 52% to GBP153.5 million. Profit before tax and adjusting items fell, however, by 17% to GBP176.5 million. M&S booked just GBP23.0 million in adjusting items in the recent half year, compared to GBP111.7 million a year ago. This includes costs relating to strategic programmes in areas such as its UK store estate and IT restructure. Like-for-like sales growth in the Food unit was 0.9% in the half-year, driven by volume. Clothing & Home like-for-like sales, meanwhile, fell 5.5%. M&S said it saw an improved Clothing & Home performance in October following a "difficult" first half.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Tyman, up 7.2%. The engineered components supplier reported an improved performance in its current financial year despite "challenging" market conditions. Tyman said revenue and adjusted operating profit for the full year are expected to be ahead of 2018 and in line with current market expectations. The improved performance was helped by contributions from last year's acquisitions and the strength of the dollar against sterling. Tyman highlighted that the growth was achieved despite its markets remaining "challenging", with European and UK markets having weakened further since the end of July. Meanwhile, the London-headquartered company said North American markets continue to be broadly flat with no clear signs yet of a return to higher activity levels.

----------

Thor Mining, up 12%. The miner said it has found "visible gold" in panning samples at the recently acquired and 100% owned Pilbara goldfield in Western Australia. Thor said "visible gold" was found in 13 out of 44 sediment trap sites selected, with maximum gold occurrence of 20 "very fine" grains from one trap site. Thor Mining said a follow-up field evaluation is likely to comprise detailed stream sediment sampling, soil sampling and geological mapping. Executive Chair Mick Billing said: "These preliminary results are very exciting, and we look forward to confirmatory laboratory assays." "To obtain results of this calibre in an initial reconnaissance survey is an excellent result," Billing said.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Sound Energy, down 12%. The company said it has now agreed with an undisclosed UK company to dispose of the majority of its eastern Morocco portfolio stake for a total of USD112.8 million. Back in May, the Moroccan-focused gas company has decided to explore monetisation options for its interests in the Tendrara production concession, the Greater Tendrara petroleum agreement and the Anoual permits, with a view to assessing a sale of this eastern Morocco portfolio prior to a final investment decision. On Wednesday, Sound Energy said it has granted an unnamed purchaser an exclusivity period, expiring on February 14 next year, to finalise a binding sale & purchase agreement for 51% of Sound Energy's stake in the eastern Morocco portfolio for USD112.8 million. On completion of the transaction it is anticipated that Sound Energy will retain a 23% overall stake in the eastern Morocco portfolio. The total consideration comprises a USD54.3 million in cash, Sound Energy said, payable in tranches, and an estimated USD58.5 million carry with respect to Sound Energy's future capital expenditure requirements, relating to its retained interest in the Tendrara production concession in order to achieve first gas production.

----------

Intu Properties, down 12%. The company said it experienced difficult trading conditions in the third quarter and warned that its like-for-like net rental income will fall in 2019. Intu said leasing activity slowed in the period to September 30, with customers more reluctant to dig into their coffers due to prevailing political and economic uncertainty. Shopping centre property peer Hammerson was down 3.6%. The firm has however seen an uptick in leasing activity with retailers. Intu said it struck deals with British luxury department store Harrods, Spanish retail chain Zara, and an Alibaba Group subsidiary. Elsewhere, Intu said it was hurt by company voluntary agreements of other retailers: UK-based Monsoon Accessorize and Topshop-owner Arcadia Group. Intu explained: "We anticipate that like-for-like net rental income for 2019 will be down by around 9%, with more than half the reduction coming from the impact of CVAs such as Arcadia and Monsoon." Intu footfall was up 1.2% year-on-year in the third quarter, and the company's rental income was lifted by 4% after 34 rent reviews during the period.

----------

Breedon Group, down 11%. The construction materials firm slumped as a major shareholder sold off its entire stake. After the market close on Tuesday, JPMorgan Securities said M1 Cement Holding would be selling 139.7 million Breedon shares, 8.3% of the company. Early Wednesday, JPMorgan confirmed all of the shares had been successfully sold at a price of 59 pence each, netting M1 Cement proceeds of GBP82.4 million. Breedon received nothing from the sale, as they were existing shares. Breedon, which is based in Breedon on the Hill in Leicestershire, was 11% lower on Wednesday in London at a price of 58.00p.

----------

4D Pharma, down 8.6%. The pharmaceutical company said that initial clinical observations show that oncology candidate MRx0518 and KEYTRUDA combination is well tolerated in patients with advance disease. 4D Pharma said that clinical observation in collaboration with Merck & Co were to evaluate company's lead oncology candidate MRx0518 in combination with Merck anti-PD-1 theraphy KEYTRUDA in patients with renal cell carcinoma, melanoma, non-small cell lung cancer and bladder cancer. The initial data revealed that the combination is well tolerated in the first six patients. Two out of six patients showed clinically relevant response in the phase 1/2 study, the company said. 4D Pharma said these are the first observations from an oncology study in humans involving a live biotherapeutic product.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
15 Feb 2023 14:21

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June 2022.

Read more
3 Feb 2023 15:17

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2023 15:58

UK shareholder meetings calendar - next 7 days

Tuesday 10 January 
Valereum Blockchain PLCAGM
Wishbone Gold PLCAGM
Wednesday 11 January 
AB Dynamics PLCAGM
Asos PLCAGM
Edge Performance VCT PLCGM re deed of release
Hurricane Energy PLCAGM
Induction Healthcare Group PLCAGM
MetalNRG PLCGM requisitioned to remove chair and CEO from board
Synthomer PLCGM re sale of laminates business
Thursday 12 January 
JPMorgan Japanese Investment Trust PLCAGM
Friday 13 January 
eEnergy Group PLCGM re shareholder resolution to adopt the 2022 Accounts
Monday 16 January 
4D Pharma PLCGM re update on administration and suspension of trading
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
30 Dec 2022 17:21

4D Pharma seeks approval for equity fundraise to lift suspension

(Alliance News) - 4D Pharma PLC on Friday said it was seeking shareholder approval for a USD15.0 million cash raise, as it works to lift its suspension and restore its shares to trading.

Read more
16 Nov 2022 17:00

4D Pharma says trial results show Blautix eases IBS symptoms

(Alliance News) - 4D Pharma PLC said on Wednesday that its Blautix phase 2 clinical trial results showed the treatment had a positive effect on sufferers of irritable bowel syndrome

Read more
24 Aug 2022 11:44

IN BRIEF: 4D Pharma publishes pre-clinical research for autism

4D Pharma PLC - Leeds, England-based pharmaceutical company - Releases its publication of pre-clinical research on mice regarding live biotherapeutic MRx0006 for the treatment of autism spectrum disorder. Says research shows LBP MRx0006 can attenuate core behavioural deficits in a mouse model of autism, improving social deficits, repetitive and anxiety-like behaviours. "Mechanistically, MRx0006 increased in the brains of ASD mice the expression of neuropeptide hormones known to regulate social and anxiety behaviour," 4D Pharma adds.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
1 Jul 2022 20:05

TRADING UPDATES: Capital wins contracts; 4D pharma pauses enrolment

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Friday and not separately reported by Alliance News:

Read more
28 Jun 2022 21:23

IN BRIEF: 4D Pharma shares to be delisted from Nasdaq

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says it has received written notice from the Nasdaq Stock Market that its securities will be delisted from Nasdaq. Accordingly, trading of its shares will be suspended from the opening of business on July 7. Nasdaq staff cited 4D's announcement that it had been placed into administration on Friday as raising "public interest concerns". The exchange also mentioned concerns regarding the residual equity interest of existing shareholders of listed securities.

Read more
24 Jun 2022 19:09

IN BRIEF: 4d Pharma faces uncertain future as loan repayment due

4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has "no immediate certainty" of how it will repay the USD13.9 million loan facility it has with Oxford Finance LLC.

Read more
24 Jun 2022 14:33

IN BRIEF: 4d Pharma suspends trading immediately, pending announcement

4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has ordered an immediate suspension of trading in the company's shares on AIM pending a further announcement.

Read more
24 Jun 2022 12:35

4D Pharma requests immediate suspension of its shares

(Sharecast News) - Biotherapeutics developer 4D Pharma requested an immediate suspension of trading in its shares on Friday.

Read more
21 Jun 2022 16:05

UK shareholder meetings calendar - next 7 days

Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Union Jack Oil PLCAGM
Zinnwald Lithium PLCAGM
Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
27 May 2022 10:46

4D Pharma reports progress in bladder cancer trial

(Sharecast News) - Live biotherapeutics developer 4D Pharma announced progress in the phase 2 clinical trial in bladder cancer on Friday.

Read more
27 May 2022 09:31

IN BRIEF: 4D Pharma plans to test MRx0518 in combination with Bavencio

4D Pharma PLC - Leeds, England-based pharmaceutical company - Plans to conduct a phase II study to assess the safety of MRx0518 in combination with Bavencio. Says the study will be conducted in patients with unresectable locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. Says previous data about MRx0518 supports the potential of this combination to "significantly enhance and improve" outcomes for patients, beyond treatment with Bavencio alone. Bavencio is an antibody medication for the treatment of urothelial carcinoma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.